Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

C. Lance Cowey, Chirag Amin, Raj S. Pruthi, Eric M. Wallen, Matthew E. Nielsen, Gayle Grigson, Cathy Watkins, Keith V. Nance, Jeffrey Crane, Mark Jalkut, Dominic T. Moore, William Y. Kim, Paul A. Godley, Young E. Whang, Julia R. Fielding, W. Kimryn Rathmell

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Purpose: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting. Patients and Methods: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. Results: Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. Conclusion: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)1502-1507
Number of pages6
JournalJournal of Clinical Oncology
Volume28
Issue number9
DOIs
StatePublished - Mar 20 2010

Fingerprint

Renal Cell Carcinoma
Clinical Trials
Nephrectomy
Neoplasms
Therapeutics
Preoperative Period
Safety
sorafenib
Protein-Tyrosine Kinases
Kidney

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cowey, C. L., Amin, C., Pruthi, R. S., Wallen, E. M., Nielsen, M. E., Grigson, G., ... Rathmell, W. K. (2010). Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. Journal of Clinical Oncology, 28(9), 1502-1507. https://doi.org/10.1200/JCO.2009.24.7759

Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. / Cowey, C. Lance; Amin, Chirag; Pruthi, Raj S.; Wallen, Eric M.; Nielsen, Matthew E.; Grigson, Gayle; Watkins, Cathy; Nance, Keith V.; Crane, Jeffrey; Jalkut, Mark; Moore, Dominic T.; Kim, William Y.; Godley, Paul A.; Whang, Young E.; Fielding, Julia R.; Rathmell, W. Kimryn.

In: Journal of Clinical Oncology, Vol. 28, No. 9, 20.03.2010, p. 1502-1507.

Research output: Contribution to journalArticle

Cowey, CL, Amin, C, Pruthi, RS, Wallen, EM, Nielsen, ME, Grigson, G, Watkins, C, Nance, KV, Crane, J, Jalkut, M, Moore, DT, Kim, WY, Godley, PA, Whang, YE, Fielding, JR & Rathmell, WK 2010, 'Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma', Journal of Clinical Oncology, vol. 28, no. 9, pp. 1502-1507. https://doi.org/10.1200/JCO.2009.24.7759
Cowey, C. Lance ; Amin, Chirag ; Pruthi, Raj S. ; Wallen, Eric M. ; Nielsen, Matthew E. ; Grigson, Gayle ; Watkins, Cathy ; Nance, Keith V. ; Crane, Jeffrey ; Jalkut, Mark ; Moore, Dominic T. ; Kim, William Y. ; Godley, Paul A. ; Whang, Young E. ; Fielding, Julia R. ; Rathmell, W. Kimryn. / Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 9. pp. 1502-1507.
@article{17ac0bcc3e1a4652a755c56e2d75c0fd,
title = "Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma",
abstract = "Purpose: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting. Patients and Methods: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. Results: Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6{\%}) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13{\%}), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. Conclusion: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.",
author = "Cowey, {C. Lance} and Chirag Amin and Pruthi, {Raj S.} and Wallen, {Eric M.} and Nielsen, {Matthew E.} and Gayle Grigson and Cathy Watkins and Nance, {Keith V.} and Jeffrey Crane and Mark Jalkut and Moore, {Dominic T.} and Kim, {William Y.} and Godley, {Paul A.} and Whang, {Young E.} and Fielding, {Julia R.} and Rathmell, {W. Kimryn}",
year = "2010",
month = "3",
day = "20",
doi = "10.1200/JCO.2009.24.7759",
language = "English (US)",
volume = "28",
pages = "1502--1507",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma

AU - Cowey, C. Lance

AU - Amin, Chirag

AU - Pruthi, Raj S.

AU - Wallen, Eric M.

AU - Nielsen, Matthew E.

AU - Grigson, Gayle

AU - Watkins, Cathy

AU - Nance, Keith V.

AU - Crane, Jeffrey

AU - Jalkut, Mark

AU - Moore, Dominic T.

AU - Kim, William Y.

AU - Godley, Paul A.

AU - Whang, Young E.

AU - Fielding, Julia R.

AU - Rathmell, W. Kimryn

PY - 2010/3/20

Y1 - 2010/3/20

N2 - Purpose: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting. Patients and Methods: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. Results: Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. Conclusion: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.

AB - Purpose: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting. Patients and Methods: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. Results: Of the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. Conclusion: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=77951886671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951886671&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.24.7759

DO - 10.1200/JCO.2009.24.7759

M3 - Article

VL - 28

SP - 1502

EP - 1507

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -